- Home
- STRS vs NBTX Comparison
STRS vs NBTX Comparison
Compare STRS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRS
- NBTX
- Stock Information
- Founded
- STRS 1992
- NBTX 2003
- Country
- STRS United States
- NBTX France
- Employees
- STRS N/A
- NBTX N/A
- Industry
- STRS Homebuilding
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- STRS Real Estate
- NBTX Health Care
- Exchange
- STRS Nasdaq
- NBTX Nasdaq
- Market Cap
- STRS 218.2M
- NBTX 201.9M
- IPO Year
- STRS N/A
- NBTX 2020
- Fundamental
- Price
- STRS $18.80
- NBTX $2.87
- Analyst Decision
- STRS
- NBTX Strong Buy
- Analyst Count
- STRS 0
- NBTX 1
- Target Price
- STRS N/A
- NBTX $12.00
- AVG Volume (30 Days)
- STRS 8.6K
- NBTX 45.1K
- Earning Date
- STRS 11-13-2024
- NBTX 09-18-2024
- Dividend Yield
- STRS N/A
- NBTX N/A
- EPS Growth
- STRS N/A
- NBTX N/A
- EPS
- STRS 0.19
- NBTX N/A
- Revenue
- STRS $48,157,000.00
- NBTX $45,220,186.00
- Revenue This Year
- STRS N/A
- NBTX N/A
- Revenue Next Year
- STRS N/A
- NBTX N/A
- P/E Ratio
- STRS $96.90
- NBTX N/A
- Revenue Growth
- STRS 83.12
- NBTX 526.17
- 52 Week Low
- STRS $18.28
- NBTX $2.76
- 52 Week High
- STRS $30.66
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- STRS 33.40
- NBTX 37.64
- Support Level
- STRS $19.20
- NBTX $2.82
- Resistance Level
- STRS $21.61
- NBTX $3.07
- Average True Range (ATR)
- STRS 0.91
- NBTX 0.20
- MACD
- STRS -0.09
- NBTX 0.02
- Stochastic Oscillator
- STRS 14.02
- NBTX 10.42
About STRS Stratus Properties Inc.
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.